S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Average 126% gains – NO losers!?   (Ad)pixel
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Average 126% gains – NO losers!?   (Ad)pixel
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Average 126% gains – NO losers!?   (Ad)pixel
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Average 126% gains – NO losers!?   (Ad)pixel
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
NASDAQ:QTNT

Quotient - QTNT Stock Forecast, Price & News

$0.24
0.00 (0.00%)
(As of 08/10/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.23
$0.24
50-Day Range
$0.24
$0.53
52-Week Range
$0.23
$3.43
Volume
1.71 million shs
Average Volume
1.39 million shs
Market Capitalization
$24.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.25

Quotient MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
853.0% Upside
$2.25 Price Target
Short Interest
Healthy
1.94% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.83
Upright™ Environmental Score
News Sentiment
0.12mentions of Quotient in the last 14 days
Based on 9 Articles This Week
Insider Trading
Acquiring Shares
$1.44 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.66) to ($0.31) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.69 out of 5 stars

Medical Sector

73rd out of 1,108 stocks

Diagnostic Substances Industry

3rd out of 17 stocks

QTNT stock logo

About Quotient (NASDAQ:QTNT) Stock

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ SDS Microarray that is designed as a serological disease screening microarray comprised assays to detect cytomegalovirus and Syphilis; MosaiQ MDS Microarray that is designed as a molecular disease screening microarray test for donor red cells or source plasma; MosaiQ IH Microarray as a blood grouping microarray; MosaiQ Autoimmune Microarray; MosaiQ COVID-19; and MosaiQ IH3 Microarray. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.

Quotient Stock Performance

Quotient stock remained flat at $0.24 during midday trading on Wednesday. The company had a trading volume of 1,706,517 shares, compared to its average volume of 1,393,519. The business has a 50-day simple moving average of $0.30 and a 200-day simple moving average of $0.75. Quotient has a 12 month low of $0.23 and a 12 month high of $3.43. The firm has a market capitalization of $24.37 million, a price-to-earnings ratio of -0.20 and a beta of 2.74.

Quotient (NASDAQ:QTNT - Get Rating) last announced its earnings results on Friday, June 24th. The company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.34) by $0.09. During the same period in the previous year, the firm earned ($0.39) EPS. On average, analysts expect that Quotient will post -0.66 EPS for the current year.

Wall Street Analyst Weigh In

QTNT has been the subject of several analyst reports. Cowen dropped their target price on Quotient from $9.00 to $3.00 and set an "outperform" rating for the company in a report on Wednesday, June 29th. BTIG Research lowered their price target on Quotient from $9.00 to $1.50 and set a "buy" rating for the company in a report on Wednesday, June 29th. StockNews.com assumed coverage on Quotient in a report on Monday. They set a "hold" rating for the company. Cowen lowered their price target on Quotient from $9.00 to $3.00 and set an "outperform" rating for the company in a report on Wednesday, June 29th. Finally, The Goldman Sachs Group lowered their price target on Quotient from $3.00 to $1.50 and set a "neutral" rating for the company in a report on Tuesday, April 19th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Quotient currently has an average rating of "Moderate Buy" and an average price target of $2.25.

Insider Activity at Quotient

In other news, Director Zubeen Shroff bought 4,666,666 shares of the stock in a transaction that occurred on Friday, June 24th. The stock was bought at an average cost of $0.30 per share, for a total transaction of $1,399,999.80. Following the acquisition, the director now directly owns 11,995,740 shares of the company's stock, valued at approximately $3,598,722. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders bought 4,818,140 shares of company stock worth $1,440,354 in the last three months. 10.50% of the stock is owned by company insiders.

Receive QTNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quotient and its competitors with MarketBeat's FREE daily newsletter.

QTNT Stock News Headlines

Form 8-K Quotient Ltd For: Aug 09 - StreetInsider.com
Quotient (QTNT) Scheduled to Post Quarterly Earnings on Tuesday
Quotient (NASDAQ:QTNT) Now Covered by Analysts at StockNews.com
See More Headlines
Receive QTNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quotient and its competitors with MarketBeat's FREE daily newsletter.

QTNT Company Calendar

Last Earnings
6/24/2022
Today
8/11/2022
Next Earnings (Estimated)
11/21/2022
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:QTNT
Fax
N/A
Employees
426
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.25
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+853.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-125,130,000.00
Net Margins
-317.38%
Pretax Margin
-322.40%

Debt

Sales & Book Value

Annual Sales
$38.51 million
Book Value
($1.40) per share

Miscellaneous

Free Float
92,378,000
Market Cap
$24.37 million
Optionable
Optionable
Beta
2.74

Key Executives

  • Mr. Manuel O. Mendez (Age 54)
    CEO & Director
    Comp: $10.22M
  • Mr. Ali Kiboro (Age 47)
    Chief Financial Officer
    Comp: $798.9k
  • Mr. Mohammad El Khoury (Age 62)
    Chief Commercial Officer
    Comp: $544.83k
  • Ms. Vittoria Bonasso (Age 46)
    Head of Fin., Group Controller & Principal Accounting Officer
  • Dr. Michael Hausmann
    Chief Technology Officer
  • Dr. Christine Ginocchio
    Chief Scientific & Medical Officer
  • Mr. Christian Albrich (Age 58)
    Chief People Officer
  • Mr. Esteban Uriarte
    Chief Manufacturing Operations Officer
  • Mr. Steven Zuiderwijk
    Chief Strategy & Bus. Devel. Officer













QTNT Stock - Frequently Asked Questions

Should I buy or sell Quotient stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quotient in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" QTNT shares.
View QTNT analyst ratings
or view top-rated stocks.

What is Quotient's stock price forecast for 2022?

4 analysts have issued 1-year price targets for Quotient's shares. Their QTNT share price forecasts range from $1.50 to $3.00. On average, they predict the company's stock price to reach $2.25 in the next year. This suggests a possible upside of 853.0% from the stock's current price.
View analysts price targets for QTNT
or view top-rated stocks among Wall Street analysts.

How have QTNT shares performed in 2022?

Quotient's stock was trading at $2.59 at the beginning of 2022. Since then, QTNT stock has decreased by 90.9% and is now trading at $0.2361.
View the best growth stocks for 2022 here
.

Are investors shorting Quotient?

Quotient saw a decline in short interest during the month of July. As of July 31st, there was short interest totaling 2,000,000 shares, a decline of 25.4% from the July 15th total of 2,680,000 shares. Based on an average trading volume of 2,410,000 shares, the days-to-cover ratio is currently 0.8 days.
View Quotient's Short Interest
.

When is Quotient's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our QTNT earnings forecast
.

How were Quotient's earnings last quarter?

Quotient Limited (NASDAQ:QTNT) posted its quarterly earnings data on Friday, June, 24th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.09. During the same quarter in the prior year, the company posted ($0.39) earnings per share.

What guidance has Quotient issued on next quarter's earnings?

Quotient updated its FY 2023 earnings guidance on Tuesday, August, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $39.00 million-$42.00 million, compared to the consensus revenue estimate of $40.87 million.

What other stocks do shareholders of Quotient own?

What is Quotient's stock symbol?

Quotient trades on the NASDAQ under the ticker symbol "QTNT."

Who are Quotient's major shareholders?

Quotient's stock is owned by many different retail and institutional investors. Top institutional investors include Walleye Capital LLC (2.91%). Insiders that own company stock include Edward Farrell, Frederick Hallsworth, Jeremy Stackawitz, Khoury Mohammad El, Manuel O Mendez, Perceptive Advisors Llc, Peter Buhler, Prondzynski Heino Von, Roland Boyd and Zubeen Shroff.
View institutional ownership trends
.

How do I buy shares of Quotient?

Shares of QTNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Quotient's stock price today?

One share of QTNT stock can currently be purchased for approximately $0.24.

How much money does Quotient make?

Quotient (NASDAQ:QTNT) has a market capitalization of $24.37 million and generates $38.51 million in revenue each year. The company earns $-125,130,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis.

How many employees does Quotient have?

The company employs 426 workers across the globe.

How can I contact Quotient?

Quotient's mailing address is B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262. The official website for the company is www.quotientbd.com. The company can be reached via phone at (122) 716-9800 or via email at ir@quotientbd.com.

This page (NASDAQ:QTNT) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.